- Home
- OPHC vs KLRS Comparison
OPHC vs KLRS Comparison
Compare OPHC & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- KLRS
- Stock Information
- Founded
- OPHC 2000
- KLRS 2019
- Country
- OPHC United States
- KLRS United States
- Employees
- OPHC N/A
- KLRS N/A
- Industry
- OPHC Major Banks
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPHC Finance
- KLRS Health Care
- Exchange
- OPHC Nasdaq
- KLRS Nasdaq
- Market Cap
- OPHC 48.3M
- KLRS 46.0M
- IPO Year
- OPHC N/A
- KLRS N/A
- Fundamental
- Price
- OPHC $4.08
- KLRS $5.05
- Analyst Decision
- OPHC
- KLRS Strong Buy
- Analyst Count
- OPHC 0
- KLRS 3
- Target Price
- OPHC N/A
- KLRS $21.50
- AVG Volume (30 Days)
- OPHC 39.0K
- KLRS 97.2K
- Earning Date
- OPHC 11-10-2025
- KLRS 11-12-2025
- Dividend Yield
- OPHC N/A
- KLRS N/A
- EPS Growth
- OPHC 87.39
- KLRS N/A
- EPS
- OPHC 1.28
- KLRS N/A
- Revenue
- OPHC $43,818,000.00
- KLRS N/A
- Revenue This Year
- OPHC N/A
- KLRS N/A
- Revenue Next Year
- OPHC N/A
- KLRS N/A
- P/E Ratio
- OPHC $3.18
- KLRS N/A
- Revenue Growth
- OPHC 26.98
- KLRS N/A
- 52 Week Low
- OPHC $3.53
- KLRS $2.14
- 52 Week High
- OPHC $5.90
- KLRS $16.56
- Technical
- Relative Strength Index (RSI)
- OPHC 58.75
- KLRS 52.16
- Support Level
- OPHC $3.94
- KLRS $4.50
- Resistance Level
- OPHC $4.10
- KLRS $5.24
- Average True Range (ATR)
- OPHC 0.06
- KLRS 0.41
- MACD
- OPHC 0.01
- KLRS 0.01
- Stochastic Oscillator
- OPHC 100.00
- KLRS 60.97
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.